Introduction
============

Hepatocellular carcinoma (HCC) is a major health problem. It is the fifth most common type of cancer worldwide and the third most common cause of cancer-related death [@B1]-[@B3]. The prognosis for untreated HCC is poor in general, and the curative treatments for this disease comprise surgical resection, radiofrequency ablation, and liver transplantation [@B1]-[@B3]. Noncurative therapies for HCC include transcatheter arterial chemoembolization (TACE), radioembolization, molecular targeting therapies such as sorafenib, and radiation therapy [@B1]-[@B8].

Societal aging implies that the number of elderly patients with malignancy will rise in the future [@B9]. In Japan, 75-year-old men and women have an average expected life span of around 5 and 10 years, respectively, and Japan has the greatest longevity in the world [@B10]. The risk of developing HCC is known to be age-dependent, and patients aged ≥75 years sometimes present with HCC [@B11], [@B12]. The increased longevity of the population means that more elderly patients with HCC are to be expected in the coming years. In Japan, the adjusted HCC mortality has increased in recent years [@B13]. Moreover, the average age of patients with HCC in Japan is increasing, as is the proportion of elderly patients with HCC [@B14]. Thus, there is an urgent need to identify the optimal management for HCC in elderly patients.

TACE is a procedure whereby an embolic agent is injected into the tumor-feeding artery to deprive the tumor of its major nutrient source by means of embolization; this results in ischemic necrosis of the targeted tumor [@B8]. The survival benefit of TACE in patients with unresectable HCC was established in two randomized controlled trials and one meta-analysis [@B15]-[@B17]. Thus, TACE plays an important role in the treatment of unresectable HCC. It is clearly defined as a first-line therapy with a better 2-year survival rate than that of conservative therapy [@B18]. The Barcelona Clinic Liver Cancer (BCLC) intermediate stage (BCLC-B) includes Child-Pugh A and B patients with multifocal HCC, defined as more than three tumors of any size or two to three tumors with a maximal diameter of ≤3 cm and a single HCC of ≤5 cm [@B18]-[@B21]. The BCLC classification indicates that these patients are optimal candidates for TACE [@B18], [@B19].

Advanced age was previously considered to be a contraindication for TACE in the treatment of HCC [@B22]. There are few data regarding the clinical outcome in elderly patients with intermediate HCC undergoing TACE [@B21], [@B23]-[@B26] and most of them are reported from countries other than Japan. Furthermore, the BCLC classification does not stratify strategies according to age [@B18], [@B19]. Whether elderly patients with intermediate HCC who undergo TACE have a prognosis comparable with that of younger patients with intermediate HCC who undergo TACE therefore remains elusive [@B21], [@B23]-[@B25]. The aim of the present study was to compare clinical outcomes between elderly patients with intermediate HCC undergoing TACE and younger patients with intermediate HCC undergoing TACE.

Materials and Methods
=====================

*Patients.* We performed TACE as an initial treatment in 150 treatment-naive patients diagnosed with intermediate-stage HCC in the Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Japan between December 2003 and December 2012. Of these patients, 147 were treated with TACE using an epirubicin-mitomycin-lipiodol (EML) emulsion, and three were treated with TACE using a miriplatin-lipiodol emulsion. We categorized them into two groups: the elderly group (≥75 years old, n=66) and the control group (\<75 years old, n=84). The breakpoint of 75 years of age was chosen because in Japan, patients aged ≥75 years are covered by a health insurance system that differs from that for patients aged \<75 years. We compared the clinical outcomes including overall survival (OS), tumor response rate, and safety between these two groups. Patients diagnosed with HCC rupture at initial therapy were not included in this study because they were treated with transcatheter arterial embolization without chemoembolization.

Written informed consent was obtained from all patients prior to each therapy, and the study protocol complied with all provisions of the Declaration of Helsinki. This study was approved by the Ethics Committee of Osaka Red Cross Hospital, Japan, and the need for written informed consent was waived because the data were analyzed retrospectively and anonymously. The present study comprised a retrospective analysis of patient records registered in our database, and all treatments were conducted in an open-label manner.

*HCC diagnosis.*HCC was diagnosed using abdominal ultrasound and dynamic computed tomography (CT) scans (hyperattenuation during the arterial phase in all or some part of the tumor and hypoattenuation in the portal-venous phase) and/or magnetic resonance imaging (MRI), based mainly on the recommendations of the American Association for the Study of Liver Diseases [@B18]. Arterial- and portal-phase dynamic CT images were obtained at approximately 30 and 120 s, respectively, after the injection of the contrast material. When carrying out angiography, we also confirmed the presence of intermediate-stage HCC using CT during hepatic arteriography (CTHA) and CT during arterial portography (CTAP) [@B27], [@B28].

*TACE procedure.*In our angiography room, a catheter was advanced to the superior mesenteric artery, and CTAP was performed to investigate the site and size of the HCC. Furthermore, we confirmed the patency of the portal vein at the time of postmesenteric portography. A catheter was then advanced to the celiac artery, and a microcatheter was advanced to the common hepatic artery or proper hepatic artery through a catheter. This approach was used to perform CTHA and digital subtraction angiography with the purpose of investigating the tumor vascularity and identifying the feeding vessels. After the completion of these procedures, a microcatheter was advanced as close as possible to the feeding vessels of the targeted tumor. This was followed by intra-arterial infusion of an anticancer agent and lipiodol emulsion via the feeding arteries according to tumor size and liver function [@B20], [@B29], [@B30]. After the infusion of the anticancer agent and lipiodol emulsion, gelatin sponge particles were slowly injected into the feeding arteries to prevent reflux into untreated segments. The sites of injection of the embolizing agents were segmental or subsegmental in all patients treated with TACE. When patients had poor liver function, the doses of the anticancer agents and lipiodol were reduced.

*Assessment of treatment efficacy.*Treatment efficacy was evaluated using CT findings within 2 months after the initial treatment. We regarded lipiodol accumulation in targeted tumors seen on CT scans as an indication of necrosis. This was because several studies previously reported that the lipiodol retention areas observed on CT corresponded to necrotic areas [@B31], [@B32]. A complete response (CR) was defined as the disappearance of all targeted tumors or 100% tumor necrosis, a partial response (PR) was defined as a ≥50% reduction in tumor size and/or necrosis, and progressive disease (PD) was defined as ˃25% tumor enlargement and/or the appearance of any new HCC tumors. Stable disease (SD) was defined as disease that did not qualify for classification as CR, PR, or PD.

*Follow-up.*Follow-up after each therapy comprised periodic blood tests and monitoring of tumor markers, including α-fetoprotein and *des*-γ-carboxy prothrombin. Dynamic CT scans and/or MRI were obtained every 2 to 4 months after each therapy. Chest CT, whole abdominal CT, brain MRI, and bone scintigraphy were performed when extrahepatic HCC recurrence was suspected. When disease progression of the treated HCC lesions was observed after the initial therapy and/or new hepatic lesions were observed, the most appropriate treatments were performed if the liver functional reserve was adequate and if patients did not refuse such therapies. These treatments included transcatheter arterial therapies in most cases. However, when the treated lesion was well controlled after the initial therapy and the new lesion appeared in the liver, percutaneous ablative therapies were also considered. In cases that were refractory to transcatheter arterial therapies or those involving extrahepatic metastases, a molecular targeting therapy such as sorafenib was also considered [@B33].

*Statistical analysis.*Data were analyzed using univariate and multivariate analyses. Continuous variables were compared using the unpaired *t*-test, and categorical variables were compared using Fisher\'s exact test. For analysis of OS, follow-up ended at the time of death from any cause, and the remaining patients were censored at the last follow-up visit. The cumulative OS rates were calculated using the Kaplan-Meier method and tested using the log-rank test. Factors with a *p* value of \<0.05 in univariate analysis were subjected to multivariate analysis using the Cox proportional hazards model. These statistical methods were used to estimate the interval from initial treatment. Data were analyzed using SPSS software (SPSS Inc., Chicago, IL, USA) for Microsoft Windows. Data are expressed as the mean ± standard deviation. Values of *p*\<0.05 were considered to be statistically significant.

Results
=======

*Baseline characteristics.*The baseline characteristics of the patients in the two groups are shown in Table [I](#TI){ref-type="table"}. The median observation periods were 1.6 years (range, 0.2-5.3 years) in the elderly group and 1.9 years (range, 0.2-9.0 years) in the control group. There was a significantly higher proportion of female patients, a lower positivity rate for hepatitis B surface antigen, and a lower body mass index (BMI) in the elderly group. The serum albumin level, prothrombin time (PT), and platelet count were significantly higher in the elderly group than in the control group, and the proportion of patients with Child-Pugh class A disease was significantly higher in the elderly group than in the control group. These findings indicated that patients in the elderly group had a liver functional reserve superior to that of patients in the control group. No significant difference was observed in comorbid diseases between the two groups.

*Median survival time and cumulative OS rates.*The median survival time (MST) and the 1-, 3-, and 5-year cumulative OS rates were 2.90 years and 84.1%, 48.0%, and 15.0%, respectively, in the elderly group and 2.44 years and 78.2%, 39.3%, and 33.8%, respectively, in the control group; there was no significant difference between the two groups (*p*=0.887) (Figure [1](#F1){ref-type="fig"}).

*Mean doses of anticancer agents and lipiodol in the two groups.*In the elderly group, TACE using EML emulsion containing epirubicin (Farmorubicin; Pfizer) at a mean dose of 39.1 ± 9.8 mg, mitomycin (Mitomycin C; Kyowa Hakko Kirin Company, Ltd., Tokyo, Japan) at a mean dose of 8.8 ± 3.3 mg, and lipiodol at a mean dose of 5.9 ± 2.8 ml was performed in 65 patients, and TACE using miriplatin-lipiodol emulsion containing miriplatin (Miripla; Dainippon Sumitomo, Tokyo, Japan) at a dose of 140 mg and lipiodol at a dose of 7 ml was performed in 1 patient [@B29], [@B30], [@B34]. In the control group, TACE using EML emulsion containing epirubicin at a mean dose of 39.3 ± 10.9 mg, mitomycin at a mean dose of 8.9 ± 3.1 mg, and lipiodol at a mean dose of 5.6 ± 2.7 ml was performed in 82 patients, and TACE using miriplatin-lipiodol emulsion containing miriplatin at a dose of 120 mg and lipiodol at a dose of 6 ml was performed in 2 patients [@B29], [@B30], [@B34].

*Treatment efficacy at initial treatment in the two groups.*In the elderly group, a CR was achieved in 10 patients, a PR in 44 patients, SD in 11 patients, and PD in 1 patient. Thus, the objective response rate (ORR) in the elderly group was 81.8% (54/66 patients). In the control group, a CR was achieved in 20 patients, a PR in 46 patients, SD in 18 patients, and PD in 0 patients. Thus, the ORR in the TACE group was 78.6% (66/84 patients). The difference in initial treatment efficacy between the two groups did not reach significance (*p*=0.227).

*Univariate and multivariate analyses of factors contributing to OS.*Univariate analysis identified the following factors as being significantly associated with OS for all cases (n=150): the Child-Pugh classification (*p*\<0.001), tumor number of ≤5 (*p*=0.001), tumor distribution (*p*=0.001), maximum tumor size of ≤4.5 cm (*p*=0.008), objective tumor response at initial treatment (*p*=0.004), serum albumin level of ≥3.7 g/dl (*p*=0.014), and total bilirubin level of ≥1.0 mg/dl (*p*=0.011) (Table [II](#TII){ref-type="table"}). The hazard ratios and 95% confidence intervals calculated using multivariate analysis for the eight factors with *p*-values of \<0.05 in the univariate analysis are detailed in Table [II](#TII){ref-type="table"}. The Child-Pugh classification (*p*=0.039), tumor number of ≤5 (*p*=0.018), maximum tumor size of ≤4.5 cm (*p*=0.048), and ORR at initial therapy (*p*=0.010) were found to be significant predictors linked to OS in multivariate analysis.

*Causes of death.*Thirty-two patients in the elderly group (48.5%) died during the follow-up period. The causes of death were HCC progression in 24 patients, liver failure in 4 patients, and miscellaneous causes in 4 patients. Fifty-two patients in the control group (61.9%) died during the follow-up period, and the causes of death were HCC progression in 29 patients, liver failure in 19 patients, and miscellaneous causes in 4 patients.

*Adverse events and hospitalization days in the two groups.*In both groups, symptoms associated with postembolization syndrome such as fever, appetite loss, abdominal pain, and nausea were transient and mostly resolved within 2 weeks after initial treatment [@B35]. In the elderly group, serious adverse events (SAEs) were observed in three patients (4.5%). Each of these three patients had one of the following SAEs: cholangitis, aspiration pneumonia, or liver abscess formation. All of these SAEs were managed successfully. Thus, TACE-related mortality in the elderly group was 0%. In the control group, SAEs were observed in five patients (6.0%). Each of these five patients had one of the following SAEs: acute respiratory distress syndrome (ARDS), hepatic encephalopathy, hyponatremia, hyperbilirubinemia, or refractory ascites. All of these SAEs were managed successfully, although in one patient who developed ARDS, management in the intensive care unit was required. Thus, TACE-related mortality in the control group was 0%. The mean number of hospitalization days in the elderly group tended to be less than that in the control group (10.7 ± 5.0 *vs.*12.6 ± 6.7 days, respectively; *p*=0.053).

*Subgroup analyses according to the Child-Pugh classification.*A significant difference was observed between the two groups in terms of the Child-Pugh classification (*p*=0.019), and we therefore performed subgroup analyses according to this classification. No significant difference (*p*=0.390) was observed between the two groups in terms of OS in patients with Child-Pugh class A disease (53 patients \[80.3%\] in the elderly group and 52 patients \[61.9%\] in the control group); the MST was 3.62 years in the elderly group and 3.32 years in the control group (Figure [2](#F2){ref-type="fig"}A). Similarly, no significant difference (*p*=0.434) was found between the two groups in terms of OS in patients with Child-Pugh class B disease (13 patients \[19.7%\] in the elderly group and 32 \[38.1%\] in the control group); the MST was 2.10 years in the elderly group and 1.72 years in the control group (Figure [2](#F2){ref-type="fig"}B).

*Subgroup analyses according to maximum tumor size.*Although there were no significant differences in baseline tumor characteristics between the two groups, tumor-related characteristics are reportedly prognostic factors associated with OS in patients with HCC undergoing TACE [@B8], [@B15]-[@B17]. Hence, we performed subgroup analyses according to maximum tumor size. No significant difference (*p*=0.861) was observed between the two groups in terms OS in patients with a maximum tumor size of ≥4.5 cm (39 patients \[59.1%\] in the elderly group and 38 \[45.2%\] in the control group); the MST was 2.41 years in the elderly group and 1.88 years in the control group (Figure [3](#F3){ref-type="fig"}A). Similarly, no significant difference (*p*=0.559) was found between the two groups in terms of OS in patients with a maximum tumor size of \<4.5 cm (27 patients \[40.9%\] in the elderly group and 46 \[54.8%\] in the control group); the MST was 3.78 years in the elderly group and 2.92 years in the control group (Figure [3](#F3){ref-type="fig"}B).

*Subgroup analyses according to gender and other factors.*Since a significant difference of proportion of male patients was observed between the two groups, we performed subgroup analyses according to gender. In male patients (34 patients in the elderly group and 63 in the control group), the MST was 2.68 years in the elderly group and 2.56 years in the control group (*p*=0.986). In female patients (32 patients in the elderly group and 21 in the control group), the MST was 3.62 years in the elderly group and 2.10 years in the control group (*p*=0.885). In subgroup analyses of other factors \[tumor number (\>5 or ≤5), presence or absence of ORR, tumor distribution (bilobar or unilobar), pretreatment serum albumin level (≥3.7g/dl or \<3.7g/dl) and total bilirubin (≥1mg/dl or \<1mg/dl)\], no significant difference was observed in the two groups in terms of OS (data not shown).

Discussion
==========

In Japan, there is a trend toward an increasing number of elderly patients with HCC. In addition, the latest estimates suggest that the incidence of HCC peaks above the age of 70 years worldwide [@B36]. However, few investigators have reported the clinical outcome in elderly patients with intermediate-stage HCC who underwent TACE as initial therapy, although there are several studies on the clinical outcome in elderly patients with HCC who underwent surgical resection or ablative therapies [@B21], [@B23]-[@B26], [@B37]-[@B47]. Hence, we conducted the current comparative study.

Our results showed no significant difference in OS or treatment efficacy at initial therapy between the elderly group and the control group, and similar results were obtained in all subgroup analyses. These findings indicate that elderly patients with intermediate-stage HCC who underwent TACE had a prognosis comparable with that of younger patients. Cohen et al. reported that the MST in patients with HCC aged ≥75 years treated with TACE was 1.88 years, while in our study, the MST in the elderly group was 2.90 years [@B25]. Because the baseline characteristics differed between their study and ours, it may not be possible to reach a definitive conclusion. However, our TACE procedure may have been more effective than that of Cohen et al.

In the present study, a significantly higher proportion of female patients and a lower positivity rate for hepatitis B surface antigen were found in the elderly group than in the control group and patients in the elderly group had a liver functional reserve superior to that of patients in the control group. In previous studies, elderly patients with HCC were more likely to be women [@B37]-[@B47]. This may have been associated with a larger female elderly population because of their longer life expectancy [@B39]. The fact that male tend to drink and smoke more than female in general may also be associated with our observations, although in this study, drinking history and smoking history are not exactly taken from all studied subjects. Furthermore, as in our study, elderly patients with HCC were more likely to have hepatitis C virus (HCV) than hepatitis B virus (HBV) carriers in many previous studies [@B37]-[@B47]. This finding may be explained by the fact that most HBV carriers acquire the virus via vertical transmission in the perinatal period, whereas most HCV carriers are infected at a later stage in life. HCC therefore manifests as a complication in HCV carriers much later in life than in HBV carriers [@B40]-[@B47]. Interestingly, however, the elderly group had a significantly lower BMI than that of the control group. Hepatic steatosis is significantly correlated with an increasing BMI and results in accelerated liver carcinogenesis [@B48]-[@B50]. These facts may be related to our observations.

In our multivariate analysis, the Child-Pugh classification, tumor number of ≤5, maximum tumor size of ≤4.5cm, and ORR at initial therapy were significant predictors associated with OS. Takayasu et al. reported in their large study that the degree of liver damage, alpha-fetoprotein level, maximum tumor size, number of lesions, and degree of portal vein invasion were significant factors linked to OS according to their multivariate analysis [@B8]. Our results are consistent with their reports.

In general, elderly patients have a significantly higher proportion of comorbid diseases than younger patients [@B24], [@B25], [@B37]-[@B47] However, our baseline characteristics showed no significant difference in comorbid diseases between the two groups. Elderly patients with HCC with severe or numerous comorbid diseases may be excluded from the current analysis because of the expected TACE-related SAEs. The fact that the proportion of patients with Child-Pugh B disease was significantly lower in the elderly group than in the control group may be also due to the same reason.

In our study, TACE-related mortality was 0% in both groups. TACE-related mortality reportedly ranges from 0.5% to 7% [@B8], [@B21], [@B23]. Furthermore, the mean number of hospitalization days in the elderly group tended to be fewer than that in the control group. Our safety profile of TACE in elderly patients with HCC is encouraging.

This study had several limitations. First, it was a retrospective study over the period of 10 years. Thus, diagnostic procedure and treatment procedure for HCC may not be consistent in each patient, leading to bias. Second, the sample sizes in the two cohorts were small for analysis. Third, as mentioned earlier, elderly patients with severe comorbid diseases may be excluded from this analysis, also potentially leading to bias. Larger prospective comparative studies will therefore be needed in the future to confirm these results. However, our study results demonstrated that the elderly group had a prognosis comparable with that in the control group and that our TACE procedure was safe.

In conclusion, elderly patients with intermediate-stage HCC undergoing TACE had a prognosis comparable with that of younger patients with intermediate-stage HCC undergoing TACE. TACE for elderly patients with intermediate-stage HCC should not be withheld based on advanced age alone.
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###### 

Baseline characteristics between the elderly group and the control group.

  Variables                              Elderly group (n=66)   Control group (n=84)   P value
  -------------------------------------- ---------------------- ---------------------- ------------
  Age (years)                            80.8 ± 4.2             65.7 ± 5.6             \<0.001^a^
  Gender, male/female                    34 / 32                63 / 21                0.003^b^
  Maximum tumor size (cm)                5.7 ± 2.8              5.1 ± 3.2              0.220^a^
  Tumor distribution, bilobar/unilobar   23 / 43                37 / 47                0.314^b^
  Tumor number, \>5 vs. ≤5               14 / 52                21 / 63                0.698^b^
  Child-Pugh classification                                                            
  Child-Pugh A / B                       53 / 13                52 / 32                0.019^b^
  Causes of liver disease                                                              
  B/C/non B and non C/B and C            0 / 47 / 19 / 0        13 / 49 / 21 / 1       0.003^b^
  Efficacy of initial TACE                                                             
  CR/PR/SD/PD                            10/44/11/1             20/46/18/0             0.227^b^
  AST (IU/L)                             58.2 ± 29.6            63.8 ± 34.0            0.289^a^
  ALT (IU/L)                             43.5 ± 27.9            52.9 ± 37.7            0.095^a^
  ALP (IU/L)                             383.6 ± 193.4          439.1 ± 235.8          0.124^a^
  GGT (IU/L)                             119.0 ± 182.6          157.3 ± 211.1          0.244^a^
  Serum albumin (g/dL)                   3.78 ± 0.48            3.53 ± 0.52            0.003^a^
  Total bilirubin (mg/dL)                0.95 ± 0.64            1.15 ± 0.96            0.151^a^
  Prothrombin time (%)                   88.4 ± 18.4            81.0 ± 17.0            0.012^a^
  Platelets (×10^4^/mm^3^)               15.6 ± 7.7             12.4 ± 6.5             0.007^a^
  AFP (ng/mL)                            1367.6 ± 3614.3        1250.8 ± 3679.8        0.846^a^
  DCP (mAU/mL)                           7046.4 ± 19775.1       10076.1 ± 42352.1      0.563^a^
  Duration of hospitalization (days)     10.7 ± 5.0             12.6 ± 6.7             0.053^a^
  Body mass index (kg/m^2^)              21.8 ± 3.7             24.6 ± 3.6             \<0.001^a^
  Comorbid diseases                                                                    
  Hypertension, yes/no                   44 / 22                43 / 41                0.068^b^
  Cardiovascular disease, yes/no         14 / 52                12 / 72                0.285^b^
  Respiratory disease, yes/no            4 / 62                 7 / 77                 0.756^b^
  Cerebrovascular disease, yes/no        11 / 55                13 / 71                \>0.999^b^
  Diabetes mellitus, yes/no              19 / 47                35 / 49                0.124^b^
  Serum creatinine (mg/dL)               0.98 ± 0.49            0.90 ± 0.37            0.270^a^

Data are expressed as number or mean ± standard deviation. TACE; transcatheter arterial chemoembolization, CR; complete response, PR; partial response, SD; stable disease, PD; progressive disease, AST; aspartate aminotransferase, ALT; alanine aminotransferase, ALP; alkaline phosphatase, GGT; gamma glutamyl transpeptidase, AFP; alpha-fetoprotein, DCP; des-γ-carboxy prothrombin, ^a;^unpaired t test, ^b;^Fisher^,^s exact test.

###### 

Univariate and multivariate analysis contributing to overall survival.

  ----------------------------------------------------------------------------------------------------------
  Variables                                         n          Univariate\   Multivariate Analysis   
                                                               Analysis                              
  ------------------------------------------------- ---------- ------------- ----------------------- -------
  Gender, male *vs.* female                         97 / 53    0.952                                 

  Age (years), ≥75 *vs.* \<75                       66 / 84    0.887                                 

  Child-Pugh, A *vs.* B                             105 / 45   \<0.001       0.524 (0.283-0.969)     0.039

  Tumor number, \>5 *vs.* ≤5                        35 / 115   0.001         0.489 (0.270-0.885)     0.018

  Tumor distribution, bilobar *vs.* unilobar        60 / 90    0.001         1.128 (0.632-2.016)     0.683

  Maximum tumor size, ≥4.5cm *vs.* \<4.5cm          73 / 77    0.008         0.633 (0.402-0.996)     0.048

  Objective response at initial therapy, yes / no   120 / 30   0.004         2.017(1.180-3.448)      0.010

  AST (IU / L), ≥50 *vs.*\< 50                      83 / 67    0.188                                 

  ALT (IU / L), ≥ 40 *vs.* \< 40                    77 / 73    0.992                                 

  ALP (IU / L), ≥ 360 *vs.* \< 360                  73 / 77    0.060                                 

  GGT (IU / L), ≥ 80 *vs.* \< 80                    73 / 77    0.322                                 

  Serum albumin level (g / dL), ≥3.7 *vs.*\<3.7     74 / 76    0.014         1.219 (0.690-2.154)     0.496

  Total bilirubin (mg / dL), ≥1.0 *vs.* \<1.0       59 / 91    0.011         0.766 (0.472-1.243)     0.281

  Platelet count (×10^4^/ mm^3^), ≥13 *vs.* \<13    73 / 77    0.937                                 

  Prothrombin time (%), ≥87 *vs.* \<87              73 / 77    0.070                                 

  Serum creatinine (mg / dL), ≥1.0 *vs.* \<1.0      45 / 105   0.926                                 

  Diabetes mellitus, yes/no                         54/96      0.423                                 

  Body mass index (kg/m^2^), ≥23 vs. \<23           74/76      0.835                                 

  Serum AFP (ng / mL), ≥40 *vs.* \<40               72 / 78    0.166                                 

  DCP (mAU / mL), ≥800 *vs.* \<800                  79 / 71    0.069                                 
  ----------------------------------------------------------------------------------------------------------

CI; confidence interval, AST; aspartate aminotransferase, ALT; alanine aminotransferase, ALP; alkaline phosphatase, GGT; gamma glutamyl transpeptidase, AFP, alpha-fetoprotein; DCP, des-γ-carboxy prothrombin, ^a;^Cox proportional hazard model.
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